Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | 10% owner | November 24, 2025 | December 18, 2025 |
| Mitesco, Inc.tnty · Entity 8540 | Director | February 07, 2017 | March 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date November 24, 2025 · Filed December 18, 2025
Jointly reported with 10X Fund, L.P., 10X Capital Management, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,614,457 |
Last balance in matching sequence
After 2025-12-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-11-24 · Other · Disposed 24,000 · Balance 5,645,138 F1: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Row 2 · 2025-12-16 · Sale · Disposed 30,681 · Balance 5,614,457 F3: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law.
F2: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3: The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Mitesco, Inc.
Report date February 07, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 100,000 |
| Restricted Common StockSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2017-02-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 200,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2022 Filed Feb 4, 2022 23:23 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.10 | $21,000.00 |
DisclosureSEC source: 0001493152-22-003302 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,178,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 21:42 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-22-000033 · form4.xml · derivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-24 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2022. Read SEC document |
| January 12, 2022 Filed Dec 1, 2023 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 4,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-043431 · ownership.xml · nonDerivative · entry 3 CZIRR JAMES C · CIK 0001260641 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,616 F1 · kind: Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5. F1 · price: Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5. Read SEC document |
| January 12, 2022 Filed Dec 1, 2023 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 4,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-043431 · ownership.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,616 F1 · kind: Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5. F1 · price: Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5. Read SEC document |
| January 12, 2022 Filed Dec 1, 2023 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GiftCommon Stock | 4,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-043431 · ownership.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 760,616 F1 · kind: Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5. F1 · price: Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 20:42 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.10 | $21,000.00 |
DisclosureSEC source: 0001493152-22-001148 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,188,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 17:42 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.37 | $23,700.00 |
DisclosureSEC source: 0001493152-21-030546 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,198,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 01, 2021 Filed Nov 4, 2021 15:55 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.19 | $31,900.00 |
DisclosureSEC source: 0001493152-21-027207 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,208,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 19:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.37 | $33,700.00 |
DisclosureSEC source: 0001493152-21-025776 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,218,940 F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 16:00 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.62 | $36,200.00 |
DisclosureSEC source: 0001493152-21-024757 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,228,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 13:00 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.91 | $39,100.00 |
DisclosureSEC source: 0001493152-21-021935 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,238,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 19:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.25 | $32,500.00 |
DisclosureSEC source: 0001493152-21-018420 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,248,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 09, 2021 Filed Jul 15, 2021 18:27 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.54 | $35,400.00 |
DisclosureSEC source: 0001493152-21-016934 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,258,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:27 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.91 | $39,100.00 |
DisclosureSEC source: 0001493152-21-013547 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,268,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001493152-21-010442 · ownership.xml · nonDerivative · entry 4 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:05 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001493152-21-010480 · ownership.xml · nonDerivative · entry 5 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,278,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 28, 2021 Filed May 5, 2021 16:05 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $5.02 | $50,200.00 |
DisclosureSEC source: 0001493152-21-010480 · ownership.xml · nonDerivative · entry 4 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 26, 2021 Filed May 4, 2021 20:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 7,500 | $4.47 | $33,525.00 |
DisclosureSEC source: 0001493152-21-010442 · ownership.xml · nonDerivative · entry 3 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,298,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 26, 2021 Filed May 5, 2021 16:05 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 7,500 | $4.47 | $33,525.00 |
DisclosureSEC source: 0001493152-21-010480 · ownership.xml · nonDerivative · entry 3 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,298,940 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 23, 2021 Filed May 4, 2021 20:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 5,000 | $3.95 | $19,750.00 |
DisclosureSEC source: 0001493152-21-010442 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,306,440 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 23, 2021 Filed May 5, 2021 16:05 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 5,000 | $3.95 | $19,750.00 |
DisclosureSEC source: 0001493152-21-010480 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,306,440 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 22, 2021 Filed May 4, 2021 20:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 5,000 | $3.52 | $17,600.00 |
DisclosureSEC source: 0001493152-21-010442 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,311,440 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 22, 2021 Filed May 5, 2021 16:05 UTC Amendment | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 5,000 | $3.52 | $17,600.00 |
DisclosureSEC source: 0001493152-21-010480 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,311,440 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:48 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.16 | $21,600.00 |
DisclosureSEC source: 0001493152-21-007950 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,316,440 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013815 · doc4.xml · derivative · entry 2 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013815 · doc4.xml · derivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such options vest 100% on March 31, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.31 | $23,100.00 |
DisclosureSEC source: 0001493152-21-005375 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,326,440 F1 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 15:47 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.04 | $20,400.00 |
DisclosureSEC source: 0001493152-21-002719 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,336,440 F2 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:36 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.23 | $22,300.00 |
DisclosureSEC source: 0001493152-21-000241 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,346,440 F2 · kind: Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 21:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.97 | $29,700.00 |
DisclosureSEC source: 0001493152-20-019507 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director 10X Capital Management, LLC · CIK 0001457247 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,356,440 F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 17, 2020 Filed Jan 21, 2020 21:54 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 10,000 | $2.97 | $29,700.00 |
DisclosureSEC source: 0001493152-20-000877 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375,790 F2 · kind: Shares sold pursuant to 10X Fund, LP's Quarterly Liquidity Program. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 23:02 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-20-001120 · doc4.xml · derivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-01-09 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2020. Read SEC document |
| November 18, 2019 Filed Feb 13, 2020 21:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 9,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-002223 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · 10% owner CZIRR JAMES C · CIK 0001260641 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,366,440 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| October 23, 2019 Filed Feb 13, 2020 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-002229 · ownership.xml · nonDerivative · entry 2 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767,616 F4 · kind: Shares transferred to ex-spouse pursuant to a divorce decree. Transaction does not constitute a sale pursuant to existing court rulings and SEC interpretative guidance. F3 · price: Amount beneficially owned is different from prior reports by 14 shares as a result of the erroneous reporting in Form 5 for 2018 fiscal year of the receipt of 1,000 shares as a stock dividend on Series A Convertible Stock on September 30, 2018. Mr. Czirr, actually received 986 as a stock dividend. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 10:56 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 17,000 | $3.73 | $63,325.00 |
DisclosureSEC source: 0001493152-19-015454 · ownership.xml · nonDerivative · entry 2 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,385,790 F2 · kind: Shares sold pursuant to 10X Fund, LP's Quarterly Liquidity Program. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 30, 2019 Filed Feb 13, 2020 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 1,000 | $6.00 | $6,000.00 |
DisclosureSEC source: 0001493152-20-002229 · ownership.xml · nonDerivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,616 F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 9/30/2019. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions. F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 9/30/2019. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. F3 · balance_after: Amount beneficially owned is different from prior reports by 14 shares as a result of the erroneous reporting in Form 5 for 2018 fiscal year of the receipt of 1,000 shares as a stock dividend on Series A Convertible Stock on September 30, 2018. Mr. Czirr, actually received 986 as a stock dividend. Read SEC document |
| August 02, 2019 Filed Oct 15, 2019 10:56 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 38,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-19-015454 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,402,790 F3 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security pursuant to applicable law. F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 15, 2019 Filed Jul 25, 2019 10:03 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 306 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-19-011073 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,441,480 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security pursuant to applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security pursuant to applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 03, 2019 Filed Jun 12, 2019 17:13 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | OtherCommon Stock | 67,515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-19-009040 · ownership.xml · nonDerivative · entry 1 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,441,786 F1 · kind: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F1 · price: Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law. F2 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:19 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000016 · edgar.xml · derivative · entry 1 CZIRR JAMES C · CIK 0001260641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The options vest 100% on January 16, 2020. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-3 Preferred Stock · Derivative | 1,008,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 18 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 896,997 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-3 Preferred Stock · Derivative | 1,125,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 17 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 753,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-3 Preferred Stock · Derivative | 375,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 16 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 139,211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-2 Preferred Stock · Derivative | 285,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 15 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-2 Preferred Stock · Derivative | 155,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 14 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-2 Preferred Stock · Derivative | 167,500 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 13 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 111,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-2 Preferred Stock · Derivative | 162,500 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 12 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-2 Preferred Stock · Derivative | 162,500 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 11 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-2 Preferred Stock · Derivative | 155,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 10 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 103,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| January 11, 2019 Filed Apr 1, 2019 21:59 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | ConversionSeries B-2 Preferred Stock · Derivative | 162,500 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001493152-19-004630 · ownership.xml · derivative · entry 9 10X Fund, L.P. · CIK 0001453356 · 10% owner 10X Capital Management, LLC · CIK 0001457247 · General Partner CZIRR JAMES C · CIK 0001260641 · Managing Member of GP Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6. F1 · derivative.exercise_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F1 · derivative.expiration_date: Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual. F3 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.